Related Experiment Video
Updated: Jul 15, 2026
06:06
Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
Published on: May 9, 2022
2.5K
Oral Lichen Planus Successfully Treated With Upadacitinib
Journal of Drugs in Dermatology : JDD
|April 2, 2024
Summary
Janus kinase (JAK) inhibitors offer new hope for inflammatory skin conditions. A case study shows upadacitinib, an oral JAK1 inhibitor, effectively treated severe oral lichen planus unresponsive to other therapies.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) pathways are crucial in inflammatory processes.
- Emerging JAK and STAT inhibitors show promise for treating refractory inflammatory dermatoses.
- Oral lichen planus is a chronic inflammatory condition with limited treatment options.
Observation:
- A patient with severe oral lichen planus, unresponsive to multiple standard treatments, was enrolled.
- The patient was treated with upadacitinib, an oral selective JAK1 inhibitor.
Findings:
- Upadacitinib treatment resulted in a 70% improvement in oral lichen planus symptoms within one month.
- The patient experienced significant symptom relief and functional improvement.
Implications:
- This case highlights the potential of upadacitinib as a targeted therapy for severe oral lichen planus.
- JAK1 inhibition may represent a novel therapeutic strategy for difficult-to-treat inflammatory skin conditions.
- Further research is warranted to explore the efficacy and safety of upadacitinib in a broader patient population.
Related Concept Videos
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...